<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nata Bakuradze</style></author><author><style face="normal" font="default" size="100%">Merabishvili, Maia</style></author><author><style face="normal" font="default" size="100%">Ia Kusradze</style></author><author><style face="normal" font="default" size="100%">Pieter-Jan Ceyssens</style></author><author><style face="normal" font="default" size="100%">Jolien Onsea</style></author><author><style face="normal" font="default" size="100%">Willem-Jan Metsemakers</style></author><author><style face="normal" font="default" size="100%">Nino Grdzelishvili</style></author><author><style face="normal" font="default" size="100%">Guliko Natroshvili</style></author><author><style face="normal" font="default" size="100%">Tamar Tatrishvili</style></author><author><style face="normal" font="default" size="100%">Davit Lazvliashvili</style></author><author><style face="normal" font="default" size="100%">Nunu Mitskevich</style></author><author><style face="normal" font="default" size="100%">Pirnay, Jean-Paul</style></author><author><style face="normal" font="default" size="100%">Chanishvili, Nina</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterization of a Bacteriophage GEC_vB_Bfr_UZM3 Active against .</style></title><secondary-title><style face="normal" font="default" size="100%">Viruses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-Bacterial Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacteriophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacteroides fragilis</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Apr 25</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;is a commensal gut bacterium that is associated with a number of blood and tissue infections. It has not yet been recognized as one of the drug-resistant human pathogens, but cases of the refractory infections, caused by strains that are not susceptible to the common antibiotic regimes established for have been more frequently reported. Bacteriophages (phages) were found to be a successful antibacterial alternative to antibiotic therapy in many cases of multidrug-resistant (MDR) bacterial infections. We have characterized the bacteriophage GEC_vB_Bfr_UZM3 (UZM3), which was used for the treatment of a patient with a chronic osteomyelitis caused by a mixed infection. Studied biological and morphological properties of UZM3 showed that it seems to represent a strictly lytic phage belonging to a siphovirus morphotype. It is characterized by high stability at body temperature and in pH environments for about 6 h. Whole genome sequencing analysis of the phage UZM3 showed that it does not harbor any known virulence genes and can be considered as a potential therapeutic phage to be used against infections.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record></records></xml>